Brief: RenovoRx Announces Positive New Data From Phase III Clinical Trial Interim Analysis
30/03/2023 14:50
March 30 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ANNOUNCES POSITIVE NEW DATA FROM PHASE III
CLINICAL
TRIAL INTERIM ANALYSIS: 60% SURVIVAL BENEFIT AND FEWER SIDE
EFFECTS THAN SYSTEMIC CHEMOTHERAPY
* RENOVORX INC - RENOVOGEM PATIENTS HAD GREATER THAN 65%
REDUCTION
IN SIDE EFFECTS
* RENOVORX INC - WILL BE ADVANCING DISCUSSIONS WITH FDA
ABOUT
EXPEDITING FORWARD PROGRESS FOR RENOVOGEM
Source text for Eikon: ID:nBw8pp1YYa
Further company coverage: RNXT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer